Palvella Therapeutics (PVLA) EBIAT: 2013-2024
Historic EBIAT for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' EBIAT fell 110.21% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 193.27%. This contributed to the annual value of -$17.4 million for FY2024, which is 193.27% down from last year.
- As of Q4 2024, Palvella Therapeutics' EBIAT stood at -$4.0 million, which was up 41.68% from -$6.8 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' EBIAT registered a high of $38.7 million during Q4 2023, and its lowest value of -$16.5 million during Q3 2021.
- In the last 3 years, Palvella Therapeutics' EBIAT had a median value of -$5.9 million in 2022 and averaged -$2.7 million.
- As far as peak fluctuations go, Palvella Therapeutics' EBIAT tumbled by 1,695.51% in 2020, and later skyrocketed by 576.20% in 2023.
- Palvella Therapeutics' EBIAT (Quarterly) stood at -$14.4 million in 2020, then skyrocketed by 33.81% to -$9.5 million in 2021, then increased by 14.76% to -$8.1 million in 2022, then surged by 576.20% to $38.7 million in 2023, then slumped by 110.21% to -$4.0 million in 2024.
- Its EBIAT was -$4.0 million in Q4 2024, compared to -$6.8 million in Q3 2024 and -$4.2 million in Q2 2024.